435 related articles for article (PubMed ID: 22762204)
1. Tumour suppressor genes in chemotherapeutic drug response.
Lai D; Visser-Grieve S; Yang X
Biosci Rep; 2012 Aug; 32(4):361-74. PubMed ID: 22762204
[TBL] [Abstract][Full Text] [Related]
2. The Hippo pathway in chemotherapeutic drug resistance.
Zhao Y; Yang X
Int J Cancer; 2015 Dec; 137(12):2767-73. PubMed ID: 25348697
[TBL] [Abstract][Full Text] [Related]
3. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.
McNeish IA; Bell SJ; Lemoine NR
Gene Ther; 2004 Mar; 11(6):497-503. PubMed ID: 14762396
[TBL] [Abstract][Full Text] [Related]
5. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
[TBL] [Abstract][Full Text] [Related]
6. The Hippo Pathway as a Driver of Select Human Cancers.
Kulkarni A; Chang MT; Vissers JHA; Dey A; Harvey KF
Trends Cancer; 2020 Sep; 6(9):781-796. PubMed ID: 32446746
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
8. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.
Mastropasqua F; Marzano F; Valletti A; Aiello I; Di Tullio G; Morgano A; Liuni S; Ranieri E; Guerrini L; Gasparre G; Sbisà E; Pesole G; Moschetta A; Caratozzolo MF; Tullo A
Mol Cancer; 2017 Mar; 16(1):67. PubMed ID: 28327152
[TBL] [Abstract][Full Text] [Related]
9. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
10. Towards the overcoming of anticancer drug resistance mediated by p53 mutations.
Cao X; Hou J; An Q; Assaraf YG; Wang X
Drug Resist Updat; 2020 Mar; 49():100671. PubMed ID: 31841768
[TBL] [Abstract][Full Text] [Related]
11. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
[TBL] [Abstract][Full Text] [Related]
12. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
13. Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.
Sun H; Ma H; Wang J; Xia L; Zhu G; Wang Z; Sun J; Chen Z
Tumour Biol; 2017 Jul; 39(7):1010428317709639. PubMed ID: 28714370
[TBL] [Abstract][Full Text] [Related]
14. Predicting drug response based on gene expression.
Robert J; Vekris A; Pourquier P; Bonnet J
Crit Rev Oncol Hematol; 2004 Sep; 51(3):205-27. PubMed ID: 15331079
[TBL] [Abstract][Full Text] [Related]
15. Targeting oncogenes and tumor suppressors genes to mitigate chemoresistance.
Fatemian T; Chowdhury EH
Curr Cancer Drug Targets; 2014; 14(7):599-609. PubMed ID: 25308718
[TBL] [Abstract][Full Text] [Related]
16. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function.
Gao L; Wu ZX; Assaraf YG; Chen ZS; Wang L
Drug Resist Updat; 2021 Jul; 57():100770. PubMed ID: 34175687
[TBL] [Abstract][Full Text] [Related]
17. The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology.
Petty RD
Clin Oncol (R Coll Radiol); 1996; 8(3):186-9. PubMed ID: 8814375
[No Abstract] [Full Text] [Related]
18. The role of PTEN signaling perturbations in cancer and in targeted therapy.
Keniry M; Parsons R
Oncogene; 2008 Sep; 27(41):5477-85. PubMed ID: 18794882
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of resistance to antifolates, a review.
Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
[TBL] [Abstract][Full Text] [Related]
20. Retinoblastoma deficiency increases chemosensitivity in lung cancer.
Zagorski WA; Knudsen ES; Reed MF
Cancer Res; 2007 Sep; 67(17):8264-73. PubMed ID: 17804741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
